Paradeep Phosphate has signed a Memorandum of Understanding (MoU) with the Government of Odisha to strengthen its production capabilities and integrate key raw materials. The company is set to invest ₹4,000 crore over 5 years, focusing on increasing phosphatic fertiliser manufacturing capacity while advancing sustainability and renewable energy initiatives.

Expansion of Manufacturing Capacity

As part of this investment, Paradeep Phosphate will enhance its intermediate and final product production while also improving port, jetty, and infrastructure facilities. This expansion will directly create employment opportunities for 100–150 individuals and indirectly benefit 700–1,000 workers. The strategic move aims to bolster agricultural productivity and ensure a stable supply of fertilisers.

Current Production and Future Growth

Paradeep Phosphate operates 2 manufacturing units in Paradeep, Odisha, and Zuarinagar, Goa, with a total production capacity of 3 million metric tonnes (MT). This includes 2.6 million MT of phosphates and 0.4 million MT of urea. The investment will further increase production efficiency, reduce environmental impact, and contribute to the sustainable growth of the agricultural sector.

Paradeep Phosphate Share Performance

As of January 31, 2025, at 10:30 AM, Paradeep Phophate’s shares are trading at ₹112.89 per share, up 0.34% from yesterday’s closing price. Over the last month, the stock has surged by 2.5% and over the past year, it has surged by 41.63%

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Info Edge (India) Ltd, the parent company of Naukri.com, has announced that its board of directors will meet on February 5 to discuss a proposal for the company’s first-ever stock split. This development has positively impacted the company’s stock performance, with shares rising by 3% in recent trading sessions.

Details of the Proposed Stock Split

A stock split is a corporate action where a company divides its existing shares into multiple new shares, thereby reducing the share price but maintaining the overall value for shareholders. For example, in a 2-for-1 stock split, shareholders will receive two shares for every share they currently hold, while the price of each share is halved. The main objective of a stock split is to make shares more affordable and accessible to a broader range of investors, which in turn can increase liquidity.

For Info Edge, the exact ratio and record date for the proposed split are still under discussion, but the move signifies the company’s intention to expand its retail investor base. The stock split also comes at a time when Info Edge has been experiencing significant growth across its various platforms, notably Naukri.com, which continues to be one of India’s leading job portals

Market Reaction

Following the announcement, Info Edge’s shares experienced a 3% increase, reflecting positive investor sentiment towards the proposed stock split. The shares of Info Edge, As of January 30, 2025, at 11:05 AM, are trading at ₹7,637.80 per share, reflecting a surge of 2.60% from the previous day’s closing price. Over the past month, the stock has registered a decline of 12.34%.

Conclusion

The upcoming board meeting to consider Info Edge’s first stock split marks a significant milestone for the company. If approved, this move could enhance the stock’s liquidity and broaden its investor base, potentially contributing to the company’s continued growth and success in the market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bajaj Healthcare Limited (BHL) has received approval from the Drug Controller General of India (DCGI) to manufacture Pimavanserin, including both its Active Pharmaceutical Ingredient (API) and drug formulation in the form of a 34 mg capsule.

The company has also extended manufacturing offers for Pimavanserin to several Indian pharmaceutical companies, ensuring that the drug is available in the domestic market.

What is Pimavanserin?

Pimavanserin is an atypical antipsychotic used to treat hallucinations and delusions in patients with Parkinson’s disease psychosis. It is marketed globally under the brand name Nuplazid and has gained recognition as a treatment option in the US antipsychotic drug market.

Presence and Global Sales

Acadia Pharmaceuticals, which sells Nuplazid, recently projected that combined net sales of Nuplazid and its other brand, Daybue, will exceed $1 billion in 2025. The drug has established itself in the US market as a preferred treatment in its category.

Background

Bajaj Healthcare was established in 1993 and manufactures APIs, intermediates, formulations, and nutraceuticals. It has operations in Europe, the US, Australia, the Middle East, and South America. The company has a market capitalization of over ₹2,100 crore.

Regulatory Disclosure

As per SEBI’s (Prohibition of Insider Trading) Regulations, 2015, the company’s trading window remains closed for directors and designated employees following its prior disclosure dated December 27, 2024.

The approval allows Bajaj Healthcare to produce Pimavanserin for the Indian market, making it available as a treatment option for Parkinson’s disease psychosis.

Market Reaction

Following the announcement, as of January 30, 12:49 PM, Bajaj Healthcare Ltd is trading at ₹637.30, down 2.90% (₹19.00) for the day, but has gained 66.38% over the past six months and 89.59% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

L&T, a USD 27 billion Indian multinational enterprise, Minerals & Metals division has secured a major contract to set up state-of-the-art freight handling facilities in the Gulf Cooperation Council (GCC) region, further strengthening its position in global infrastructure projects.

L&T Secures Key Project in the GCC Region  

Larsen & Toubro’s Minerals & Metals (M&M) division has won a major order to set up freight handling facilities in the GCC region. This order is a repeat contract from a prominent railway company in the GCC, which plans to expand its capacity in stages. The project will involve several phases including advanced automation and control systems at two different locations along with additional components.

Scope of Work and Execution  

The project involves the engineering, procurement, construction and commissioning (EPCC) of freight-handling facilities. These facilities will feature the latest automation and control technologies. L&T has a strong track record in completing similar freight handling projects both in India and the Middle East, showcasing its capabilities in delivering high-quality projects.

Strengthening M&M’s Reputation  

This new project reinforces M&M’s standing as a leader in freight handling facilities. According to Mr D K Sen, Executive Committee Member and Advisor to the CMD at L&T, the repeat order from the GCC’s largest railway company is a clear indication of L&T’s ability to consistently meet international standards in terms of quality, safety and timely project completion.

Project Classification and Value

The order is classified as a “Significant” project, valued between ₹1,000 crore and ₹2,500 crore.  

L&T’s project classification includes the following categories: 

• Large (₹2,500 to ₹5,000 crore)
• Major (₹5,000 to ₹10,000 crore)
• Mega (₹10,000 to ₹15,000 crore)
• Ultra-Mega (over ₹15,000 crore).  

L&T’s Industry Presence  

Larsen & Toubro, a $27 billion multinational company, is involved in various sectors like EPC projects, high-tech manufacturing and services. The company’s focus on customer satisfaction and maintaining top-quality standards has helped it maintain a leadership position in its key business areas for over 80 years.

L&T’s Share Performance 

As of January 30, 2025, at 12:45 PM, L&T’s shares are trading at ₹3,432.05 per share, down 0.51% from yesterday’s closing price. Over the last month, the stock has fallen by 4.10% and over the past year, it has declined by 6.42%. The stock has a 52-week high and 52-week low of ₹3,963.50 per share and ₹3,175.05 per share respectively.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

NATCO Pharma Ltd has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) in 2mg, 3mg, and 5mg strengths. The drug is a generic version of AFINITOR DISPERZ, manufactured by Novartis Pharmaceutical Corporation.

NATCO Pharma Ltd is trading at ₹1,163.80, down ₹7.20 (0.61%) today as of January 30, 12:35 PM; the stock has dropped 16.71% in the past month but remains up 33.71% over the past year.

Usage and Indication

Everolimus TFOS is used in adults and children aged one year and older who have tuberous sclerosis complex (TSC), a condition that can cause subependymal giant cell astrocytoma (SEGA). The drug is prescribed for cases where the tumour cannot be removed surgically and requires medical treatment.

Market Size and Competition

According to industry sales data, Everolimus tablets for oral suspension generated approximately $112 million in the US for the 12 months ending September 2024. NATCO’s version enters a limited-competition market, offering a lower-cost alternative to the existing brand-name drug.

NATCO’s marketing partner, Breckenridge Pharmaceutical, Inc., plans to launch the drug immediately in the US market.

Company Overview

Headquartered in Hyderabad, India, NATCO Pharma develops generic and speciality pharmaceuticals, active pharmaceutical ingredients (APIs), and crop protection products. It operates nine manufacturing facilities and two R&D centres in India. 

The company’s plants are approved by regulatory authorities such as the USFDA, Health Canada, Brazil ANVISA, and the WHO, and it supplies products to over 50 countries.

Regulatory Disclosure

The announcement was made in a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed BSE and NSE about the approval.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.